dc.contributor.author | Lau, Corinna | |
dc.contributor.author | McAdam, MB | |
dc.contributor.author | Bergseth, G | |
dc.contributor.author | Grevys, Algirdas | |
dc.contributor.author | Bruun, JA | |
dc.contributor.author | Ludviksen, Judith K | |
dc.contributor.author | Fure, Hilde | |
dc.contributor.author | Espevik, Terje | |
dc.contributor.author | Moen, A | |
dc.contributor.author | Andersen, Jan Terje | |
dc.contributor.author | Mollnes, Tom Eirik | |
dc.date.accessioned | 2020-02-03T13:27:51Z | |
dc.date.available | 2020-02-03T13:27:51Z | |
dc.date.created | 2020-01-13T16:06:05Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | mAbs. 2020, 12 (1) | nb_NO |
dc.identifier.issn | 1942-0862 | |
dc.identifier.uri | http://hdl.handle.net/11250/2639333 | |
dc.description.abstract | The mechanism of action of recombinant IgG2/4 antibodies involves blocking of their target without the induction of effector functions. Examples are eculizumab (Soliris®), which is used clinically to block complement factor C5, as well as anti-human CD14 (r18D11) and anti-porcine CD14 (rMIL2) produced in our laboratory. So far, no proper IgG2/4 control antibody has been available for controlled validation of IgG2/4 antibody functions. Here, we describe the design of a recombinant control antibody (NHDL), which was generated by combining the variable light (VL) and heavy (VH) chains from two unrelated specificities. NHDL was readily expressed and purified as a stable IgG2/4 antibody, and showed no detectable specificity toward any putative antigen present in human or porcine blood. The approach of artificial VL/VH combination may be adopted for the design of other recombinant control antibodies. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | Taylor & Francis | nb_NO |
dc.rights | Navngivelse-Ikkekommersiell 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/deed.no | * |
dc.title | NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies. | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.description.version | publishedVersion | nb_NO |
dc.source.volume | 12 | nb_NO |
dc.source.journal | mAbs | nb_NO |
dc.source.issue | 1 | nb_NO |
dc.identifier.doi | 10.1080/19420862.2019.1686319 | |
dc.identifier.cristin | 1771769 | |
dc.description.localcode | © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. | nb_NO |
cristin.unitcode | 194,65,15,0 | |
cristin.unitname | Institutt for klinisk og molekylær medisin | |
cristin.ispublished | true | |
cristin.qualitycode | 1 | |